DOCSLIB.ORG

Line Treatment of HER2-Negative Metastatic Breast Cancer. the MYME Randomized, Phase 2 Clinical Trial

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Line Treatment of HER2-Negative Metastatic Breast Cancer. the MYME Randomized, Phase 2 Clinical Trial Breast Cancer Research and Treatment (2019) 174:433–442 https://doi.org/10.1007/s10549-018-05070-2 CLINICAL TRIAL Metformin plus chemotherapy versus chemotherapy alone in the first- line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial O. Nanni1 · D. Amadori2 · A. De Censi3 · A. Rocca2 · A. Freschi4 · A. Bologna5 · L. Gianni6 · F. Rosetti7 · L. Amaducci8 · L. Cavanna9 · F. Foca1 · S. Sarti2 · P. Serra1 · L. Valmorri1 · P. Bruzzi10 · D. Corradengo3 · A. Gennari11 on behalf of MYME investigators Received: 20 November 2018 / Accepted: 23 November 2018 / Published online: 7 December 2018 © Springer Science+Business Media, LLC, part of Springer Nature 2018 Abstract Purpose To investigate the efficacy of metformin (M) plus chemotherapy versus chemotherapy alone in metastatic breast cancer (MBC). Methods Non-diabetic women with HER2-negative MBC were randomized to receive non-pegylated liposomal doxorubicin (NPLD) 60 mg/m2 + cyclophosphamide (C) 600 mg/m2 × 8 cycles Q21 days plus M 2000 mg/day (arm A) versus NPLD/C (arm B). The primary endpoint was progression-free survival (PFS). Results One-hundred-twenty-two patients were evaluable for PFS. At a median follow-up of 39.6 months (interquartile range [IQR] 24.6–50.7 months), 112 PFS events and 71 deaths have been registered. Median PFS was 9.4 months (95% CI 7.8–10.4) in arm A and 9.9 (95% CI 7.4–11.5) in arm B (P = 0.651). In patients with HOMA index < 2.5, median PFS was 10.4 months (95% CI 9.6–11.7) versus 8.5 (95% CI 5.8–9.7) in those with HOMA index ≥ 2.5 (P = 0.034). Grade 3/4 neu- tropenia was the most common toxicity, occurring in 54.4% of arm A patients and 72.3% of the arm B group (P = 0.019). M induced diarrhea (G2) was observed in 8.8% of patients in Arm A. The effect of M was similar in patients with HOMA index < 2.5 and ≥ 2.5, for PFS and OS. Conclusions The MYME trial failed to provide evidence in support of an anticancer activity of M in combination with first line CT in MBC. A significantly shorter PFS was observed in insulin-resistant patients (HOMA ≥ 2.5). Noteworthy, M had a significant effect on CT induced severe neutropenia. Further development of M in combination with CT in the setting of MBC is not warranted. Keywords Metformin · Insulin resistance · Advanced breast cancer · HOMA index Introduction DNA synthesis and cell proliferation [2]. This effect may also be attributable to the cross-activation of the insulin-like growth There is increasing evidence that the insulin pathway is factor (IGF) receptor family. Insulin-like growth factors (IGFs) involved in the development and prognosis of a variety of are endocrine mediators of growth hormones that also act in human neoplasms, including breast cancer (BC) [1]. This a paracrine and autocrine manner to regulate cell growth, dif- association is biologically plausible as hyperinsulinemia ferentiation, apoptosis, and transformation in numerous tissues induces proliferative tissue abnormalities due to the strong including the breast [3]. The downstream pathway of the insu- anabolic effect of insulin, resulting in the enhancement of lin/IGF system is well defined: IGF-I and insulin activate the tyrosine kinase growth receptor pathway, i.e., insulin, IGF-I, and hybrid IGF-I/insulin receptors, all of which are overex- The members of the MYME investigators study group are listed in pressed in breast cancer cells. Activation of these receptors the acknowledgments. results in the upregulation of the insulin receptor-substrate-2 * O. Nanni (IRS2), leading to the downstream activation of the MAPKi- [email protected] nase and PI3K-Akt pathways [4]. It has also been shown that Extended author information available on the last page of the article stimulation of the insulin receptor by insulin or IGFs enhances Vol.:(0123456789)1 3 434 Breast Cancer Research and Treatment (2019) 174:433–442 cancer cell proliferation. These findings suggest that the insu- assessing whether the addition of M to first-line chemo- lin/IGF pathway may be involved in tumor development and therapy in HER2-negative MBC is associated with a clini- progression, and might thus represent a novel therapeutic tar- cal effect, thus warranting further research. The study was get [5]. Furthermore, in patients with BC, higher circulating approved by the Ethics Committee of each participating insulin levels have been found to be associated with adverse center and was conducted in accordance with the Declara- outcome, while IGF1 levels do not appear to have such an tion of Helsinki, Good Clinical Practice norms and local impact [6, 7] . and national regulatory requirements. Written informed Within this context, it has been suggested that metformin consent was obtained from all patients before study entry. (M), the most widely prescribed anti-diabetic drug for the The study is registered in Clinicaltrials.gov (NCT01885013) treatment of hyperglycaemia and hyperinsulinemia [8], may and in European Clinical Trials Database (EudraCT No. improve prognosis in BC patients [9]. M is an oral biguanide 2009-014662-26). that inhibits hepatic gluconeogenesis and sensitizes insulin Women were eligible if they met the following criteria: action at the peripheral level. It is also widely prescribed for stage IV histologically or cytologically confirmed MBC, the treatment of type 2 diabetes [10] because of its good toler- HER2-negative disease (determined by immunohistochem- ability, and is approved by FDA for the prevention of diabetes istry [IHC] or fluorescence in situ hybridization [FISH]); in healthy at-risk subjects [11]. Pre-clinical data have shown non endocrine-responsive disease (negative hormonal sta- that the key mechanism of action of M is the through activa- tus or failure of endocrine therapy in metastatic disease); tion of the AMPK pathway, resulting in a regulation of cellular measurable and/or non-measurable disease according to energy homeostasis and an improvement in insulin sensitivity RECIST Criteria (Version 1.1) [18]; availability of HOMA [12]. Epidemiological studies on diabetic patients indicate an index calculated according to Matthews’ formula [19]; association between the use of M and reduced BC incidence prior endocrine therapy was allowed in the adjuvant and/or and mortality with respect to other antidiabetic drugs, espe- metastatic setting; prior chemotherapy was allowed in the cially in overweight/insulin-resistant women [13]. It can there- adjuvant setting providing patients had completed it at least fore be hypothesized that the potential antineoplastic effect 12 months before study entry; adjuvant anthracyclines were of M in vivo is related either to its direct effect on cancer cell allowed if prior cumulative dose did not exceed 360 mg/ metabolism or to its indirect effect through the reduction of m2 for epirubicin and 280 mg/m2 for doxorubicin; adjuvant systemic insulin levels and hyperglycaemia, especially in taxanes; age 18 to 75 years; Eastern Cooperative Oncology insulin-resistant patients. Group performance status (ECOG PS) ≤ 2; normal organ and There are little clinical data on the effect of M as an anti- bone marrow functions; and left ventricular ejection fraction cancer agent. In a large observational study of BC patients (LVEF) > 50%. Patients with known diabetes (type 1 or 2) treated with pre-operative chemotherapy, the proportion of were excluded. M-treated diabetic patients achieving a pathological com- plete response was significantly higher than that of diabetic Randomization patients treated with other antidiabetic drugs and of non- diabetic BC patients [14]. More recently, in a window of Patients were randomly assigned (1:1) with a centralized opportunity, double-blind, randomized study in early BC procedure to one of two treatment groups: first-line chemo- patients, the administration of M for 4 weeks before surgery therapy alone or chemotherapy plus M. Randomization was did not impact tumor proliferation, compared to baseline lev- performed using a computer-generated list and permuted els, in the overall patient population. However, a significant blocks within strata. Randomization was stratified by center effect of M on Ki-67 was seen in insulin-resistant patients and HOMA index (< 2.5 vs ≥ 2.5). Investigators and patients [15]. A large adjuvant trial on non-diabetic women with were not masked to treatment assignment. early BC comparing M with matching placebo in terms of disease-free survival (DFS) is currently ongoing [16, 17]. Treatment and procedures The present clinical trial evaluated the anticancer effect of M used in association with first-line chemotherapy in MBC. Eligible patients were allocated to arm A (non pegylated liposomal doxorubicin (NPLD) 60 mg/m2 intravenously (i.v.) plus cyclophosphamide (C) 600 mg/m2 i.v plus M Methods 1000 mg twice daily) or arm B (NPLD 60 mg/m2 i.v. plus C 600 mg/m2 i.v.). Chemotherapy cycles were administered Study design and participants every 21 days for a maximum of 8 cycles. M was admin- istered until disease progression. Staging procedures were The MYME (Myocet® - Metformin) trial was a phase II, performed at baseline a maximum of 28 days before ran- open-label, multicenter, randomized clinical trial aimed at domization and consisted in contrast-enhanced chest and 1 3 Breast Cancer Research and Treatment (2019) 174:433–442 435 abdominopelvic CT scan. Other tests for tumor assessment 112 patients was planned over a period of 24 months with a were performed as clinically indicated. Disease status was further follow-up of 12 months. monitored every 2 cycles (8 weeks) with the same radiologi- The primary analysis was performed on the intention- cal exams used at baseline. to-treat (ITT) population, defined as the population of Anthropometric evaluation and biochemical and hemato- randomized patients who received at least one dose of logical laboratory tests were performed at baseline (within the assigned study treatment.
Load more

Recommended publications
  • Signs and Symptoms of Metastatic Breast Cancer (Mbc)
    After Early Breast Cancer – SIGNS AND SYMPTOMS OF METASTATIC BREAST CANCER (MBC) Metastatic Breast Cancer After treatment for early or locally advanced breast cancer (stages I, II and III), it’s possible for breast cancer to return (recur) and spread to other parts of the body (metastasize). This is called metastatic breast cancer (MBC). The most common sites for breast cancer to spread are the brain, lung, liver and/or bones. It’s the most advanced stage of breast cancer, also known as stage IV breast cancer. The risk of MBC varies from person to person. Most people will not develop MBC, but it’s important to be aware of the signs and symptoms. Signs and Symptoms This picture below shows the most common signs and symptoms of MBC. If you’ve been treated for breast cancer and any of these signs or symptoms persist for 2 weeks or longer – tell your doctor. They may be related to other health conditions or side effects from treatment, but could be signs of recurrence. Brain m Attention or memory problems m Blurred vision, dizziness or headaches m Seizures m Loss of balance m Constant nausea or vomiting m Confusion or personality changes Lung m Hoarseness or constant dry cough m Shortness of breath or difficulty breathing Liver m Itchy skin or rash m Yellowing of skin or whites of eyes (jaundice) m Pain or swelling in belly m Digestive problems such as change in bowel habits or loss of appetite Bone m Bone, back, neck or joint pain m Bone fractures m Swelling Other signs and symptoms: m Fatigue m Weight loss m Difficulty urinating m Increased lymph node size under arm or other places This information is important, but remember most people with these signs and symptoms will not have MBC.
    [Show full text]
  • Mitogen-Activated Protein Kinase Signalling in Experimental Models
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PubMed Central Available online http://breast-cancer-research.com/content/11/5/209 Review Key signalling nodes in mammary gland development and cancer Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development Jacqueline Whyte1, Orla Bergin2, Alessandro Bianchi2, Sara McNally2 and Finian Martin2 1Current address: Physiology and Medical Physics, Royal College of Surgeons in Ireland, St Stephens Green, Dublin 2, Ireland 2UCD Conway Institute and School of Biomolecular and Biomedical Science University College Dublin, Belfield, Dublin 4, Ireland Corresponding author: Finian Martin, [email protected] Published: 29 September 2009 Breast Cancer Research 2009, 11:209 (doi:10.1186/bcr2361) This article is online at http://breast-cancer-research.com/content/11/5/209 © 2009 BioMed Central Ltd Abstract pathway, in particular, has been implicated as being Seven classes of mitogen-activated protein kinase (MAPK) important [3]. Signalling through each pathway involves intracellular signalling cascades exist, four of which are implicated sequential activation of a MAPK kinase kinase (MAPKKK), a in breast disease and function in mammary epithelial cells. These MAPK kinase (MAPKK) and the MAPK. Considering the are the extracellular regulated kinase (ERK)1/2 pathway, the ERK5 ERK1/2 pathway, the primary input activator is activated Ras, pathway, the p38 pathway and the c-Jun N-terminal kinase (JNK) a small GTPase. It activates Raf1 (MAPKKK), which then pathway. In some forms of human breast cancer and in many phosphorylates and activates MEK1/2 (MAPKK), which finally experimental models of breast cancer progression, signalling through the ERK1/2 pathway, in particular, has been implicated as activates ERK1/2 [1].
    [Show full text]
  • Diagnosis and Treatment of Bone Metastases in Breast Cancer: Radiotherapy, Local Approach and Systemic Therapy in a Guide for Clinicians
    cancers Review Diagnosis and Treatment of Bone Metastases in Breast Cancer: Radiotherapy, Local Approach and Systemic Therapy in a Guide for Clinicians Fabio Marazzi 1, Armando Orlandi 2, Stefania Manfrida 1 , Valeria Masiello 1,* , Alba Di Leone 3, Mariangela Massaccesi 1, Francesca Moschella 3, Gianluca Franceschini 3,4 , Emilio Bria 2,4, Maria Antonietta Gambacorta 1,4, Riccardo Masetti 3,4, Giampaolo Tortora 2,4 and Vincenzo Valentini 1,4 1 “A. Gemelli” IRCCS, UOC di Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario, 00168 Roma, Italy; [email protected] (F.M.); [email protected] (S.M.); [email protected] (M.M.); [email protected] (M.A.G.); [email protected] (V.V.) 2 “A. Gemelli” IRCCS, UOC di Oncologia Medica, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario, 00168 Roma, Italy; [email protected] (A.O.); [email protected] (E.B.); [email protected] (G.T.) 3 “A. Gemelli” IRCCS, UOC di Chirurgia Senologica, Dipartimento di Scienze della Salute della Donna e del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario, 00168 Roma, Italy; [email protected] (A.D.L.); [email protected] (F.M.); [email protected] (G.F.); [email protected] (R.M.) 4 Istituto di Radiologia, Università Cattolica del Sacro Cuore, 00168 Roma, Italy * Correspondence: [email protected] Received: 1 May 2020; Accepted: 20 August 2020; Published: 24 August 2020 Abstract: The standard care for metastatic breast cancer (MBC) is systemic therapies with imbrication of focal treatment for symptoms.
    [Show full text]
  • Insulin/IGF Axis in Breast Cancer: Clinical Evidence and Translational Insights
    biomolecules Review Insulin/IGF Axis in Breast Cancer: Clinical Evidence and Translational Insights Federica Biello 1,* , Francesca Platini 2, Francesca D’Avanzo 2, Carlo Cattrini 2 , Alessia Mennitto 2, Silvia Genestroni 2, Veronica Martini 2,3, Paolo Marzullo 1,4 , Gianluca Aimaretti 1 and Alessandra Gennari 1 1 Department of Translational Medicine, University of Eastern Piedmont, Via Solaroli 17, 28100 Novara, Italy; [email protected] (P.M.); [email protected] (G.A.); [email protected] (A.G.) 2 Division of Oncology, University Hospital “Maggiore della Carità”, 28100 Novara, Italy; [email protected] (F.P.); [email protected] (F.D.); [email protected] (C.C.); [email protected] (A.M.); [email protected] (S.G.); [email protected] (V.M.) 3 Lab of Immuno-Oncology, CAAD, Center of Autoimmune and Allergic Disease, University of Eastern Piedmont, 28100 Novara, Italy 4 Division of General Medicine, IRCCS Istituto Auxologico Italiano, Ospedale S. Giuseppe, 28921 Piancavallo-Verbania, Italy * Correspondence: [email protected] Abstract: Background: Breast cancer (BC) is the most common neoplasm in women. Many clinical and preclinical studies investigated the possible relationship between host metabolism and BC. Significant differences among BC subtypes have been reported for glucose metabolism. Insulin can promote tumorigenesis through a direct effect on epithelial tissues
    [Show full text]
  • MUC1-C Oncoprotein As a Target in Breast Cancer: Activation of Signaling Pathways and Therapeutic Approaches
    Oncogene (2013) 32, 1073–1081 & 2013 Macmillan Publishers Limited All rights reserved 0950-9232/13 www.nature.com/onc REVIEW MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches DW Kufe Mucin 1 (MUC1) is a heterodimeric protein formed by two subunits that is aberrantly overexpressed in human breast cancer and other cancers. Historically, much of the early work on MUC1 focused on the shed mucin subunit. However, more recent studies have been directed at the transmembrane MUC1-C-terminal subunit (MUC1-C) that functions as an oncoprotein. MUC1-C interacts with EGFR (epidermal growth factor receptor), ErbB2 and other receptor tyrosine kinases at the cell membrane and contributes to activation of the PI3K-AKT and mitogen-activated protein kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) pathways. MUC1-C also localizes to the nucleus where it activates the Wnt/b-catenin, signal transducer and activator of transcription (STAT) and NF (nuclear factor)-kB RelA pathways. These findings and the demonstration that MUC1-C is a druggable target have provided the experimental basis for designing agents that block MUC1-C function. Notably, inhibitors of the MUC1-C subunit have been developed that directly block its oncogenic function and induce death of breast cancer cells in vitro and in xenograft models. On the basis of these findings, a first-in-class MUC1-C inhibitor has entered phase I evaluation as a potential agent for the treatment of patients with breast cancers who express this oncoprotein. Oncogene (2013) 32, 1073–1081; doi:10.1038/onc.2012.158; published online 14 May 2012 Keywords: MUC1; breast cancer; oncoprotein; signaling pathways; targeted agents INTRODUCTION In breast tumor cells with loss of apical–basal polarity, the The mucin (MUC) family of high-molecular-weight glycoproteins MUC1-N/MUC1-C complex is found over the entire cell mem- 2 8 evolved in metazoans to provide protection for epithelial cell brane.
    [Show full text]
  • Cisplatin Based Therapy: the Role of the Mitogen Activated Protein Kinase Signaling Pathway Iman W
    Achkar et al. J Transl Med (2018) 16:96 https://doi.org/10.1186/s12967-018-1471-1 Journal of Translational Medicine REVIEW Open Access Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway Iman W. Achkar1†, Nabeel Abdulrahman2†, Hend Al‑Sulaiti2, Jensa Mariam Joseph2, Shahab Uddin1 and Fatima Mraiche2* Abstract Cisplatin is a widely used chemotherapeutic agent for treatment of various cancers. However, treatment with cisplatin is associated with drug resistance and several adverse side efects such as nephrotoxicity, reduced immunity towards infections and hearing loss. A Combination of cisplatin with other drugs is an approach to overcome drug resistance and reduce toxicity. The combination therapy also results in increased sensitivity of cisplatin towards cancer cells. The mitogen activated protein kinase (MAPK) pathway in the cell, consisting of extracellular signal regulated kinase, c-Jun N-terminal kinase, p38 kinases, and downstream mediator p90 ribosomal s6 kinase (RSK); is responsible for the regula‑ tion of various cellular events including cell survival, cell proliferation, cell cycle progression, cell migration and protein translation. This review article demonstrates the role of MAPK pathway in cisplatin based therapy, illustrates diferent combination therapy involving cisplatin and also shows the importance of targeting MAPK family, particularly RSK, to achieve increased anticancer efect and overcome drug resistance when combined with cisplatin. Keywords: Cisplatin, Mitogen activated protein kinase, p90 ribosomal s6 kinase, Combination therapy, Synergy, Apoptosis Background cisplatin induced apoptosis. Te RSK is a protein which Cisplatin has been widely used since its approval in 1978 acts as a downstream mediator of MAPK–ERK signaling against a wide spectrum of tumors including lung, ovar- pathway, and is also associated with cell survival, prolif- ian, testicular, bladder, colorectal and head and neck can- eration, cell cycle progression and migration [10–13].
    [Show full text]
  • The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives
    cancers Review The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives Maria Francesca Santolla and Marcello Maggiolini * Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy; [email protected] * Correspondence: [email protected] or [email protected] Received: 8 September 2020; Accepted: 16 October 2020; Published: 18 October 2020 Simple Summary: The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) system represents an emerging therapeutic target in breast cancer. Here, we discussed previous studies dealing with FGFR molecular aberrations, the alterations in the FGF/FGFR signaling across the different subtypes of breast cancer, the functional interplay between the FGF/FGFR axis and important components of the breast microenvironment, the therapeutic usefulness of FGF/FGFR inhibitors for the treatment of breast cancer. Abstract: One of the major challenges in the treatment of breast cancer is the heterogeneous nature of the disease. With multiple subtypes of breast cancer identified, there is an unmet clinical need for the development of therapies particularly for the less tractable subtypes. Several transduction mechanisms are involved in the progression of breast cancer, therefore making the assessment of the molecular landscape that characterizes each patient intricate. Over the last decade, numerous studies have focused on the development of tyrosine kinase inhibitors (TKIs) to target the main pathways dysregulated in breast cancer, however their effectiveness is often limited either by resistance to treatments or the appearance of adverse effects. In this context, the fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) system represents an emerging transduction pathway and therapeutic target to be fully investigated among the diverse anti-cancer settings in breast cancer.
    [Show full text]
  • Breast Cancer Type Classification Using Machine Learning
    Journal of Personalized Medicine Article Breast Cancer Type Classification Using Machine Learning Jiande Wu and Chindo Hicks * Department of Genetics, School of Medicine, Louisiana State University Health Sciences Center, 533 Bolivar, New Orleans, LA 70112, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-504-568-2657 Abstract: Background: Breast cancer is a heterogeneous disease defined by molecular types and subtypes. Advances in genomic research have enabled use of precision medicine in clinical man- agement of breast cancer. A critical unmet medical need is distinguishing triple negative breast cancer, the most aggressive and lethal form of breast cancer, from non-triple negative breast cancer. Here we propose use of a machine learning (ML) approach for classification of triple negative breast cancer and non-triple negative breast cancer patients using gene expression data. Methods: We performed analysis of RNA-Sequence data from 110 triple negative and 992 non-triple negative breast cancer tumor samples from The Cancer Genome Atlas to select the features (genes) used in the development and validation of the classification models. We evaluated four different classification models including Support Vector Machines, K-nearest neighbor, Naïve Bayes and Decision tree using features selected at different threshold levels to train the models for classifying the two types of breast cancer. For performance evaluation and validation, the proposed methods were applied to independent gene expression datasets. Results: Among the four ML algorithms evaluated, the Support Vector Machine algorithm was able to classify breast cancer more accurately into triple negative and non-triple negative breast cancer and had less misclassification errors than the other three algorithms evaluated.
    [Show full text]
  • Metastatic Breast Cancer
    Br. J. '." Br. J. Cancer (1992), 66, 318-322 © Macmillan Press Ltd., 1992 Changes in expression of o6/P4 integrin heterodimer in primary and metastatic breast cancer P.G. Natali', M.R. Nicotra2, C. Botti', M. Mottolese', A. Bigottil & 0. Segatto' 'Regina Elena Cancer Institute, Rome; 2Ist. Biomedical Technologies, CNR, Rome, Italy. Summary The a6/,B4 integrin complex has been shown to be expressed in murine tissues at the basolateral aspect of most epithelial cells including the mammary epithelium, thus suggesting that this heterodimer may interact with components of the basement membrane. Because transformation of mammary epithelium frequently results in disappearance of basement membranes and loss of cell polarisation we have analysed in the present study whether expression of the a6/P4 complex is altered in human breast tumours. The results of the present study confirm that in human mammary gland a6 and P4 subunits colocalise at the basolateral aspect of the epithelium. While in benign breast lesions this distribution pattern remains mostly unchanged, in primary carcinomas the expression of both chains is either redistributed over the cell surface or significantly reduced. This altered pattern of expression is paralleled by the lack of detection of basement membrane laminin and collagen type IV. In metastatic lesions the expression of the heterodimer is maintained in most of the lymphonodal foci, but less frequently detected in metastasis localised in the pleural cavity and in parenchymal tissues. These findings indicate that in breast epithelium expression of the x6/P4 heterodimer is modulated by the presence of basement membrane and is possibly influenced by microenvironmental factors as suggested by the different pattern of x6/P4 expression in nodal and extranodal metastatic foci.
    [Show full text]
  • Metastatic Breast Cancer in the Bone
    BONE PROTECTION FOR PEOPLE WITH METASTATIC BREAST CANCER IN THE BONE What are the Metastatic breast cancer (MBC) in signs and the bone occurs when breast cancer symptoms cells spread beyond the breast to the of bone bone (bone metastases). Even though metastases? cancer is in the bone, these are breast Signs and symptoms cancer cells. They are different from of bone metastases cancer cells that start in the bone. include: Bone is the most common site for • Bone pain, breast cancer metastases. The most • Fractures, common sites for bone metastases include the spine, skull, ribs, pelvis, • Urinary and bowel issues, long bones in the arms and legs. • Weakness in the legs How do bones work or arms; and in our body? • High levels of Bones provide support for our bodies calcium in the blood (hypercalcemia) to walk or stand. They are made up which can cause of tissues, calcium and bone cells. nausea, vomiting, Bone is always forming and breaking constipation and down in our bodies to keep bones confusion. strong and release calcium into the Blood and imaging tests blood stream. may be done to explain bone pain and confirm How do breast cancer cells affect bones? bone metastases. When breast cancer cells spread to the bones, lesions can occur. Osteolytic or lytic lesions break down bone without replacing it. These lesions are Related holes in the bone which weaken bones and cause them to break easily. It’s like holes in educational swiss cheese. resources: Osteoblastic or blastic lesions make bone that is thick and rigid. These areas of the • Metastatic Breast bone are abnormal and break more easily than normal bone.
    [Show full text]
  • Metastatic Breast Cancer
    METASTATIC BREAST CANCER What is metastatic breast cancer? Metastatic breast cancer (MBC) is breast cancer that has spread beyond the breast to other parts of the body (most often the bones, lungs, liver or brain). MBC is not a type of breast cancer, but the most advanced stage of breast cancer. It is also known as Stage IV breast cancer. An estimated 154,000 women are currently living with MBC in the U.S. About 6 percent of women have MBC when they are first diagnosed. Most cases of MBC occur when breast cancer returns at some point after treatment for early stage breast cancer. Treatment goals Currently MBC cannot be cured, but it can be treated. Treatment focuses on length and quality of life. Treatment is highly personalized. Together with your doctor, you can find the balance of treatment and quality of life that is right for you. Your treatment plan is guided by many factors, including: • Characteristics of the cancer cells (such as hormone receptor status and HER2 status) • Where the cancer has spread • Your current symptoms • Past breast cancer treatments • Your age and general health Talk with your doctors about your treatment choices. What do they suggest and why? What are the side effects of each treatment? Komen’s Questions to Ask Your Doctor downloadable cards may help you with questions to ask. You may want to join a clinical trial. Clinical trials offer the chance to try new treatments and possibly benefit from them. Your doctor can help you decide if a clinical trial is a good option for you.
    [Show full text]
  • Multilingual Cancer Glossary French | Français A
    Multilingual Cancer Glossary French | Français www.petermac.org/multilingualglossary email: [email protected] www.petermac.org/cancersurvivorship The Multilingual Cancer Glossary has been developed Disclaimer to provide language professionals working in the The information contained within this booklet is given cancer field with access to accurate and culturally as a guide to help support patients, carers, families and and linguistically appropriate cancer terminology. The consumers understand their healthand support their glossary addresses the known risk of mistranslation of health decision making process. cancer specific terms in resources in languages other than English. The information given is not fully comprehensive, nor is it intended to be used to diagnose, treat, cure or prevent Acknowledgements any medical conditions. If you require medical assistance This project is a Cancer Australia Supporting people please contact your local doctor or call Peter Mac on with cancer Grant initiative, funded by the Australian 03 8559 5000. Government. To the maximum extent permitted by law, Peter The Australian Cancer Survivorship Centre, A Richard Pratt Mac and its employees, volunteers and agents legacy would like to thank and acknowledge all parties are not liable to any person in contract, tort who contributed to the development of the glossary. (including negligence or breach of statutory duty) or We particularly thank members of the project steering otherwise for any direct or indirect loss, damage, committee and working group, language professionals cost or expense arising out of or in connection with and community organisations for their insights and that person relying on or using any information or assistance. advice provided in this booklet or incorporated into it by reference.
    [Show full text]